Sort
82,697 grants matching “vaccine development”
Development of pan-betacoronavirus vaccines
$709,989Raiees Ahmad Andrabi · University Of Pennsylvania · R01 · FY2025 · AI
Antibodies, B cells and resistance to human cryptococcosis
$709,959Liise-Anne Pirofski · Albert Einstein College Of Medicine · R01 · FY2021 · AI
RAPID VACCINATION OF HARD TO REACH POPULATI0NS
$709,936David H Vlahov · New York Academy Of Medicine · R01 · FY2006 · DA
Role of VZV Latency Transcript (VLT) and ORF63 in latency and reactivation
$709,789Paul R. Kinchington · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AI
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
$709,784Monica Gandhi · University Of California, San Francisco · R01 · FY2020 · AI
Pathogenesis of HIV and HCV in Hemophilia: HGDS
$709,778Children'S Hospital Los Angeles · R01 · FY2002 · HD
Gonococcal Vaccine Evaluation in a Humanized Mouse Model
$709,735Lee Mark Wetzler · Boston Medical Center · R01 · FY2019 · AI
Gonococcal Vaccine Evaluation in a Humanized Mouse Model
$709,735Lee Mark Wetzler · Boston Medical Center · R01 · FY2020 · AI
Gonococcal Vaccine Evaluation in a Humanized Mouse Model
$709,735Lee Mark Wetzler · Boston Medical Center · R01 · FY2018 · AI
Effectiveness and Safety of Transcatheter Left Atrial Appendage Occlusion vs. Anticoagulation in Older Adults with Atrial Fibrillation and Alzheimer's Disease and Related dementias
$709,733Joshua K Lin · Brigham And Women'S Hospital · R01 · FY2023 · AG
Development and Testing of New Tuberculosis Vaccines
$709,646Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2009 · AI
Innate Restriction Factor Modulation of Retrovirus-specific Humoral Immunity
$709,630Mario Luis Santiago · University Of Colorado Denver · R01 · FY2011 · AI
Developing a Paramyxovirus-based H5N1 Vaccine
$709,610Biao He · University Of Georgia · R01 · FY2011 · AI
Physical Resources Core
$709,596Michael Anthony Moody · Duke University · P01 · FY2017 · AI
Immune Responses and Protection in Rhesus Macaques
$709,507Amitinder Kaur · Harvard Medical School · P01 · FY2009 · AI
Leveraging Community-Academic Partnerships and Social Networks to Disseminate Vaccine-Related Information and Increase Vaccine Uptake Among Black Individuals with Rheumatic Diseases
$709,413Rosalind Ramsey-Goldman · Northwestern University At Chicago · R01 · FY2024 · AR
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies
$709,381Justin Richard Bailey · Johns Hopkins University · R01 · FY2020 · AI
Human Antibodies and Targeted Vaccines Against SARS-CoV
$709,379Wayne A. Marasco · Dana-Farber Cancer Inst · U01 · FY2008 · AI
mRNA-encoded Cas13 as a pan-respiratory antiviral
$709,376Philip J Santangelo · Emory University · R01 · FY2024 · AI
ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)
$709,372Paul A. Goepfert · University Of Alabama At Birmingham · U01 · FY2006 · AI
Practices Core
$709,325William Paul Duprex · University Of Pittsburgh At Pittsburgh · UC7 · FY2024 · AI
Broad Neutralization of HIV-1 from Rhinoviruses Displaying gp41 MPER Sequences
$709,308Gail F Arnold · Rutgers, The State Univ Of N.J. · R01 · FY2009 · AI
SPORE in Lung Cancer
$709,265Stephen B Baylin · Johns Hopkins University · P50 · FY2009 · CA
Overcome immunodominance to support the development of universal influenza vaccines
$709,236Wei Luo · Indiana University Indianapolis · R01 · FY2024 · AI
Safety and Immunogenicity of novel, live-attenuated V4020 vaccine for Venezuelan Equine Encephalitis (VEE) in healthy adults
$709,235Peter M. Pushko · Medigen, Inc. · U01 · FY2022 · AI